1095274-34-2

Upstream product

• 1095274-32-0 3-chloro-5-(4-morpholinyl)benzoic acid 
• 1095274-30-8 3-chloro-5-(4-morpholinyl)benzonitrile 
• 327056-73-5 3-fluoro-5-chlorobenzonitrile 
• 1219921-68-2 C₁₁H₁₁Cl₂NO₂ 
• 1095274-33-1 ethyl 3-chloro-5-(4-morpholinyl)benzoate 

Downstream Products

• 1095274-35-3 ethyl 3-(2-{[3-chloro-5-(4-morpholinyl)phenyl]carbonyl}hydrazino)-3-oxopropanoate 
• 1095274-37-5 {5-[3-chloro-5-(4-morpholinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetic acid 
• 1095274-36-4 ethyl {5-[3-chloro-5-(4-morpholinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetate 
• 1095273-33-8 1-[1-({5-[3-chloro-5-(4-morpholinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetyl)-4-piperidinyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 

Relevant academic research and scientific papers

Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine

A pharmacophore model was built, based on known CGRP receptor antagonists, and this was used to aid the identification of novel leads. Analogues were designed, modelled and synthesised which incorporated alternative 'LHS' fragments linked via either an amide or urea to a privileged 'RHS' fragment commonly found in CGRP receptor antagonists. As a result a novel series of oxadiazole CGRP receptor antagonists has been identified and the subsequent optimisation to enhance both potency and bioavailability is presented.

5-PHENYL-1,3,4-OXADIAZOL-2-YL-ACETYL-4-PIPERIDINYL DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The present invention relates to novel compounds that are CGRP receptor antagonists, processes for their preparation, to compositions containing them and to their use in the treatment of migraine, headache, and cluster headache.